| |
aberrant vs. normal
|
Progression free survival
|
Overall survival
|
|---|
| | |
Total N
|
Events
|
HR
|
95% C.I.
|
Wald’s p
|
Total N
|
Events
|
HR
|
95% C.I.
|
Wald’s p
|
|---|
|
Subgroup A
|
BRCA1
|
51 vs. 100
|
44 vs. 79
|
1.307
|
0.901-1.897
|
0.158
|
51 vs. 102
|
35 vs. 62
|
1.019
|
0.672-1.545
|
0.930
|
| |
ERCC1
|
43 vs. 110
|
36 vs. 88
|
1.224
|
0.829-1.806
|
0.309
|
44 vs. 111
|
30 vs. 68
|
1.169
|
0.760-1.799
|
0.478
|
| |
RRM1
|
58 vs. 95
|
49 vs. 75
|
1.348
|
0.936-1.939
|
0.108
|
59 vs. 96
|
42 vs. 56
|
1.141
|
0.760-1.715
|
0.524
|
| |
TYMS
|
78 vs. 75
|
63 vs. 61
|
0.849
|
0.593-1.216
|
0.373
|
79 vs. 76
|
50 vs. 48
|
0.871
|
0.583-1.302
|
0.500
|
|
Subgroup B
|
BRCA1
|
58 vs. 113
|
49 vs. 87
|
1.313
|
0.921-1.872
|
0.132
| | | | | |
| |
ERCC1
|
50 vs. 123
|
41 vs. 96
|
1.251
|
0.867-1.805
|
0.232
| | | | | |
| |
RRM1
|
66 vs. 107
|
55 vs. 82
|
1.371
|
0.971-1.935
|
0.073
| | | | | |
| |
TYMS
|
87 vs. 86
|
68 vs. 69
|
0.922
|
0.656-1.297
|
0.642
| | | | | |
|
Subgroup C
|
BRCA1
| | | | | |
62 vs. 123
|
38 vs. 67
|
1.003
|
0.672-1.499
|
0.987
|
| |
ERCC1
| | | | | |
53 vs. 134
|
32 vs. 74
|
1.02
|
0.672-1.548
|
0.926
|
| |
RRM1
| | | | | |
73 vs. 114
|
45 vs. 61
|
1.059
|
0.718-1.562
|
0.772
|
| |
TYMS
| | | | | |
95 vs. 92
|
56 vs. 50
|
1.027
|
0.699-1.509
|
0.892
|
- Subgroup A: 1st line, chemo-naïve; Subgroup B: 1st line, chemo-naïve and pre-treated; Subgroup C: chemo-naïve, 1st line and non-relapsed adjuvant; empty cells: not-applicable.
